Nuveen New York Municipal Value Fund Common Stock (NNY)

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Nuveen New York Municipal Value Fund as a closed-end municipal-bond portfolio, not an operating company. It invests in New York tax-exempt municipal bonds rated Baa/BBB or higher, using fundamental bottom-up credit work. That investment-grade focus is a real strength, but a fund has no durable operating moat; its results depend on credit selection, interest rates, and New York concentration. At the 2026-10-16 close of $7.82, FairStock's P/B is 0.87 and its P/E is 24.44. FairStock's Graham Number is $8.03, leaving only a 2.99% margin of safety, so the price looks fair to mildly cheap rather than a bargain. The 4.53% dividend yield and 0.38 beta suggest an income-oriented, low-volatility profile, while the 0.01 debt-to-equity ratio is low. Still, FairStock's Piotroski F-Score of 1/9 is weak, and the Altman Z-score of 149.93 is not very meaningful for a bond fund. I cannot judge growth: revenue and profit growth are not available, and the Lynch category is none because there are only 0 years of filed annual results, versus the 3 needed. With a $163.2M market cap and a 52-week range of $7.55-$8.94, I would call this a modestly discounted income vehicle, not a compelling Graham-style bargain.

In plain English: This fund owns New York tax-exempt municipal bonds, mostly rated investment grade. It looks financially weak on the limited scorecard and has almost no filed annual history. At $7.82, the price looks roughly fair to slightly cheap versus its accounting value and a simple valuation check, not deeply discounted.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-16 close · note generated 2026-10-20 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer